ALDX: Aldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for ALDX
Across the 4 sessions after earlier ALDX headlines, the stock closed higher 2 times and lower 2 times, with a median move of 3.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ALDX | SPY |
|---|---|---|---|
| Dec 16, 2025 | Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease | +33.1% | -0.3% |
| Nov 13, 2025 | Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast | -5.3% | -1.7% |
| Nov 11, 2025 | Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | +1.9% | +0.2% |
| Oct 28, 2025 | Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules | -1.7% | +0.3% |
Quantisnow market dataNASDAQ
ALDX
Aldeyra Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for ALDX
Full ALDX profile on Quantisnow Follow ALDX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time